The Alliance for Safe Biologic Medicines (ASBM) was formed in 2010 to ensure that patient safety was at the forefront of biosimilar policy discussion, by communicating the perspectives of patients and their healthcare providers.
- patients have the right to expect the same quality in drugs, whether they get the brand-name or a copy, irrespective of price
- medical decisions ought to remain between a patient and their specialist, not in the hands of regulators, legislators and insurers
- patients need full information about how biosimilars work in order to make informed choices
- while the ultimate goal is to find a balance between producing economical drugs for our patients and respecting the drug-discovery process, we must never forget that patient safety is paramount.
For more information visit the Alliance for Safe Biologic Medicines website.